- Home
- CSTL vs SNCY Comparison
CSTL vs SNCY Comparison
Compare CSTL & SNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- SNCY
- Stock Information
- Founded
- CSTL 2007
- SNCY 1982
- Country
- CSTL United States
- SNCY United States
- Employees
- CSTL N/A
- SNCY N/A
- Industry
- CSTL Medical Specialities
- SNCY Air Freight/Delivery Services
- Sector
- CSTL Health Care
- SNCY Consumer Discretionary
- Exchange
- CSTL Nasdaq
- SNCY Nasdaq
- Market Cap
- CSTL 661.7M
- SNCY 656.8M
- IPO Year
- CSTL 2019
- SNCY 2021
- Fundamental
- Price
- CSTL $33.02
- SNCY $12.42
- Analyst Decision
- CSTL Strong Buy
- SNCY Buy
- Analyst Count
- CSTL 6
- SNCY 7
- Target Price
- CSTL $38.67
- SNCY $18.86
- AVG Volume (30 Days)
- CSTL 421.5K
- SNCY 933.6K
- Earning Date
- CSTL 11-03-2025
- SNCY 10-29-2025
- Dividend Yield
- CSTL N/A
- SNCY N/A
- EPS Growth
- CSTL N/A
- SNCY 28.51
- EPS
- CSTL N/A
- SNCY 1.05
- Revenue
- CSTL $343,530,000.00
- SNCY $1,106,213,000.00
- Revenue This Year
- CSTL N/A
- SNCY $6.16
- Revenue Next Year
- CSTL N/A
- SNCY $9.63
- P/E Ratio
- CSTL N/A
- SNCY $11.92
- Revenue Growth
- CSTL 10.15
- SNCY 4.27
- 52 Week Low
- CSTL $14.59
- SNCY $8.10
- 52 Week High
- CSTL $34.64
- SNCY $18.59
- Technical
- Relative Strength Index (RSI)
- CSTL 81.56
- SNCY 56.13
- Support Level
- CSTL $23.31
- SNCY $11.86
- Resistance Level
- CSTL $34.36
- SNCY $12.76
- Average True Range (ATR)
- CSTL 1.50
- SNCY 0.62
- MACD
- CSTL 1.08
- SNCY 0.15
- Stochastic Oscillator
- CSTL 89.19
- SNCY 83.46
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.